EP2791160

MODERNA THERAPEUTICS, INC.
Application Number
EP12858350A
Filing Date
Dec 14, 2012
Status
Granted And Under Opposition
Jan 28, 2022
Grant Date
Mar 2, 2022
External Links
Slate, Register

Biblio Summary

The patent EP2791160B1 was granted on Mar 2, 2022 by Moderna Therapeutics, Inc. The patent is currently Granted And Under Opposition.

The table below shows 10 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BIONTECH SEDec 2, 2022ADMISSIBLE
ETHERNA IMMUNOTHERAPIES NVDec 2, 2022ADMISSIBLE
MAIWALD GMBHDec 2, 2022ADMISSIBLE
PFIZER INC.Dec 2, 2022ADMISSIBLE
WITHERS & ROGERS LLPDec 2, 2022ADMISSIBLE
KILBURN & STRODE LLPDec 2, 2022WITHDRAWN
SEQIRUS UK LIMITEDDec 1, 2022ADMISSIBLE
SANOFISep 26, 2022ADMISSIBLE
PATENT BOUTIQUE LLPJun 24, 2022ADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBMay 18, 2022ADMISSIBLE

The table below shows the patents of Moderna Therapeutics, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP2922554Terminally Modified RnaFeb 23, 20221
EP3019619Compositions Comprising Synthetic Polynucleotides Encoding Crispr Related Proteins And Synthetic Sgrnas And Methods Of UseAug 25, 20212
EP3492109Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses ThereofMar 4, 20202